Enanta Pharmaceuticals, Inc.
ENTA
$8.65
-$0.01-0.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.31M | 14.93M | 16.96M | 14.61M | 17.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.31M | 14.93M | 16.96M | 14.61M | 17.97M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 18.31M | 14.93M | 16.96M | 14.61M | 17.97M |
| SG&A Expenses | 10.00M | 11.39M | 12.85M | 13.68M | 13.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.21M | 39.45M | 40.50M | 44.46M | 42.16M |
| Operating Income | -18.89M | -24.53M | -23.54M | -29.85M | -24.19M |
| Income Before Tax | -18.23M | -23.95M | -22.71M | -29.19M | -23.05M |
| Income Tax Expenses | 29.00K | -1.31M | -416.00K | -363.00K | -395.00K |
| Earnings from Continuing Operations | -18.26M | -22.64M | -22.29M | -28.82M | -22.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.26M | -22.64M | -22.29M | -28.82M | -22.66M |
| EBIT | -18.89M | -24.53M | -23.54M | -29.85M | -24.19M |
| EBITDA | -17.68M | -23.32M | -22.65M | -29.38M | -23.59M |
| EPS Basic | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 |
| Normalized Basic EPS | -0.53 | -0.70 | -0.65 | -0.89 | -0.68 |
| EPS Diluted | -0.85 | -1.06 | -1.05 | -1.36 | -1.07 |
| Normalized Diluted EPS | -0.53 | -0.70 | -0.65 | -0.89 | -0.68 |
| Average Basic Shares Outstanding | 21.38M | 21.36M | 21.24M | 21.19M | 21.18M |
| Average Diluted Shares Outstanding | 21.38M | 21.36M | 21.24M | 21.19M | 21.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |